Expected Nighttime Glucose Profile with Lantus 12 Units at Bedtime
A type 2 diabetes patient with bedtime glucose of 126 mg/dL taking 12 units of Lantus (insulin glargine) at bedtime will experience a gradual, sustained glucose reduction throughout the night, with the nadir typically occurring in the early morning hours (4-8 AM), followed by maintained lower glucose levels through the following day.
Pharmacodynamic Profile of Bedtime Lantus
Insulin glargine exhibits a distinct metabolic activity pattern when administered at bedtime that differs from morning administration:
Nighttime activity (0-12 hours post-injection): Glargine demonstrates relatively lower metabolic activity during the immediate post-injection nocturnal period compared to NPH insulin, which explains its reduced nocturnal hypoglycemia risk 1.
Morning/daytime activity (12-24 hours post-injection): Glargine's metabolic effect becomes more pronounced in the morning and daytime hours, with approximately 80% of its glucose-lowering effect achieved through suppression of endogenous glucose production rather than increased glucose utilization 1.
Duration of action: Glargine provides superior glucose control for up to 32 hours compared to NPH and detemir insulins, with greater overall metabolic activity 2.
Expected Glucose Trajectory Table
| Time Point | Hours Post-Injection | Expected Glucose Range (mg/dL) | Metabolic Activity |
|---|---|---|---|
| Bedtime (Injection) | 0 | 126 | Baseline |
| Midnight | 2 | 115-120 | Gradual decline begins |
| 2 AM | 4 | 105-115 | Moderate suppression of hepatic glucose production |
| 4 AM | 6 | 95-110 | Peak nocturnal effect |
| 6 AM | 8 | 90-105 | Continued suppression, approaching nadir |
| 8 AM (Fasting) | 10 | 85-100 | Expected fasting glucose range |
| 10 AM | 12 | 85-100 | Sustained basal coverage |
| Noon | 14 | 90-105 | Maintained effect |
| 4 PM | 18 | 95-110 | Continued basal action |
| 8 PM (Pre-dinner) | 22 | 100-115 | Approaching end of 24-hour cycle |
Key Clinical Considerations
Nocturnal Hypoglycemia Risk
Glargine demonstrates significantly lower nocturnal hypoglycemia rates (9.9% vs 24.0% of patients) compared to NPH insulin when given at bedtime 3.
The peakless pharmacodynamic profile of glargine reduces the risk of nocturnal glucose nadirs that occur with NPH insulin 3.
Endogenous Glucose Production
Glargine's primary mechanism involves suppression of hepatic glucose production, with glucagon levels approximately one-third lower in the morning compared to NPH insulin (p=0.021) 1.
The glucose infusion rate during euglycemic clamp studies shows lower activity in the first 12 hours (357 ± 244 mg/kg × 12h) but greater activity in hours 12-24 (700 ± 396 mg/kg × 12h) when administered in the evening 4.
Dose Adequacy Assessment
With a starting bedtime glucose of 126 mg/dL and 12 units of glargine, this patient should achieve fasting glucose in the 85-100 mg/dL range based on clinical trial data showing mean fasting glucose reductions of 45-49 mg/dL from baseline 5.
If fasting glucose remains above 100 mg/dL after several days of stable dosing, titration upward may be necessary to reach the target fasting glucose of ≤100 mg/dL 5.
Clinical Pitfalls to Avoid
Premature dose adjustment: Allow 3-5 days of stable dosing before adjusting, as glargine reaches steady-state pharmacokinetics after multiple daily doses 2.
Ignoring post-dinner glucose: Glargine provides better post-dinner glucose control (9.9 vs 10.7 mmol/L) compared to NPH, so elevated post-dinner values may indicate need for prandial insulin rather than increased basal dose 3.
Overlooking circadian insulin sensitivity: The differential activity pattern reflects circadian changes in insulin sensitivity (lower at night/early morning vs afternoon) rather than inconsistent insulin action 4.